Don’t Miss These Late-Breaking Trials at ACC.16

ACC.16 is just around the corner, and Cleveland Clinic physicians are excited to be presenting or closely affiliated with seven late-breaking clinical trials or featured clinical research reports at the meeting.

These potentially practice-changing studies are outlined below, along with where they fit in the program at ACC.16, the American College of Cardiology’s 65th Annual Scientific Session. Be sure to make room for these presentations in your itinerary for Chicago, and look for reports and commentary on these trials from Cleveland Clinic’s Consult QD blog soon after they are presented.

PARTNER 2 final results

Session 401 — Late-Breaking Clinical Trials
Saturday, April 2, 8-10 a.m.
Transcatheter aortic valve replacement compared with surgery in intermediate-risk patients with aortic stenosis: Final results from the randomized Placement of Aortic Transcather Valves 2 (PARTNER 2) study.
Lead Cleveland Clinic investigators: Lars Svensson, MD, PhD, and Samir Kapadia, MD

ACCELERATE study of evacetrapib

Session 404 — Late-Breaking Clinical Trials
Sunday, April 3, 8-9:15 a.m.
Impact of the cholesteryl ester transfer protein inhibitor evacetrapib on cardiovascular events: Results of the ACCELERATE trial.
Presenter and Cleveland Clinic co-principal investigator: Stephen Nicholls, MBBS, PhD (A. Michael Lincoff, MD, is the other co-principal investigator)

GAUSS-3 study in statin-intolerant patients

Session 404 — Late-Breaking Clinical Trials
Sunday, April 3, 8-9:15 a.m.
Comparison of PCSK9 inhibitor evolocumab versus ezetimibe in statin-intolerant patients: The Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) trial.
Presenter and lead Cleveland Clinic investigator: Steven Nissen, MD

Sapien 3 TAVR in intermediate-risk patients

Session 405 — Late-Breaking Clinical Trials
Sunday, April 3, 10:45-noon
Sapien 3 transcatheter aortic valve replacement versus surgery in intermediate-risk patients with severe aortic stenosis: A propensity-matched comparison of one-year outcomes.
Lead Cleveland Clinic investigators: Lars Svensson, MD, PhD, and Samir Kapadia, MD

Rate vs. rhythm control post-cardiac surgery

Session 410 — Late-Breaking Clinical Trials
Monday, April 4, 8-9:15 a.m.
Rate vs. Rhythm: A randomized trial of rate control versus rhythm control for atrial fibrillation after cardiac surgery.
Presenter and lead Cleveland Clinic investigator: A. Marc Gillinov, MD

INOVATE-HF primary results

Session 412 — Late-Breaking Clinical Trials
Monday, April 4, 10:45-noon
INOVATE-HF: The effect of vagal nerve stimulation in heart failure: Primary results of the INcrease Of VAgal TonE in chronic Heart Failure (INOVATE-HF) trial.
Lead Cleveland Clinic investigator: Randall Starling, MD, MPH

STAMPEDE final results

Session 416 — Featured Clinical Research Session II
Monday, April 4, 2-3:30 p.m.
Bariatric surgery vs. intensive medical therapy for long-term glycemic control and complications of diabetes: Final 5-year STAMPEDE trial results.
Presenter and lead Cleveland Clinic investigator: Philip Schauer, MD